Vertex Pharmaceuticals Incorporated (VRTX) : 14 analysts are covering Vertex Pharmaceuticals Incorporated (VRTX) and their average rating on the stock is 1.68, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Vertex Pharmaceuticals Incorporated (VRTX) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Vertex Pharmaceuticals Incorporated (VRTX) : Currently there are 12 street experts covering Vertex Pharmaceuticals Incorporated (VRTX) stock. The most bullish and bearish price target for the stock is $155 and $75 respectively for the short term. The average price target of all the analysts comes to $116.42. The estimated standard deviation from the target is $20.26.
Also, Equity Analysts at the Brokerage Firm, Morgan Stanley, maintains their rating on the shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Morgan Stanley has a Overweight rating on the shares. As per the latest research report, the brokerage house lowers the price target to $139 per share from a prior target of $140. The rating by the firm was issued on July 28, 2016.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): After opening at $90.6, the stock dipped to an intraday low of $89.35 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $94.43 and the buying power remained strong till the end. The stock closed at $93.1 for the day, a gain of 3.31% for the day session. The total traded volume was 2,575,963. The stocks close on the previous trading day was $90.12.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.